Better Biopharma

“How can biopharma improve?” This question is the guiding ethos of the Better Biopharma podcast. Through conversations with experts across the biopharma landscape, host Tyler Menichiello explores the work being done to make better medicines and optimize manufacturing. Each episode is a dive into the guest's methods, their curiosity, and their determination. By shining a light on the visionaries pushing the industry forward, Better Biopharma aims to inform and inspire their peers to continue doing the same.

Better Biopharma is a science podcast hosted by Unknown Host, with 30 episodes on record and a Required Pod Score of 81. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts Better Biopharma, a science show with 30 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Better Biopharma

  Fixing AAV Recovery With Siren Biotechnology’s Nathalie Clément, Ph.D.

  Aug 11, 202648 min

  In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nathalie Clément, Ph.D., Siren Biotechnology’s SVP of vector development. The two discuss the historical challenges of purifying AAV vectors and the developments that have allowed for greater product yields. Clément shares where she believes the greatest gains can still be made to improve vector recovery and offers advice for teams seeking to optimize downstream unit operations. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

  ListenShow Notes
• 

  Better Biopharma

  Modulating Multispecific Manufacturability With AP Biosciences’ JJ You, Ph.D.

  Jul 14, 202639 min

  In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Jhong-Jhe You, Ph.D., VP of antibody discovery at AP Biosciences. You explains how molecular complexity and aspects of antibody design can influence a product’s manufacturability and developability. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

  ListenShow Notes
• 

  Better Biopharma

  The Facility Master Planning Playbook With Herman Bozenhardt

  Jun 30, 202658 min

  In this episode of “Better Biopharma,” host Tyler Menichiello is joined by friend-of-the-show Herman Bozenhardt, a consultant and industry veteran who has spent decades advancing the fields of biopharmaceutical manufacturing, engineering, and regulatory compliance. Bozenhardt shares practical advice for teams planning a new biomanufacturing facility or retrofitting an existing one. He explains how thoughtful facility master planning can mitigate costly design mistakes and improve site flexibility, ensuring facilities remain adaptable to future technologies, new products, and evolving regulatory expectations. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

  ListenShow Notes
• 

  Better Biopharma

  Cell Therapy Without The Cells: Building A Therapeutic Secretome With Noveome Biotherapeutics’ Larry Brown, Sc.D.

  Jun 16, 202657 min

  In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Larry Brown, Sc.D., chief scientific officer at Noveome Biotherapeutics, to discuss ST266, a first-of-its-kind secretome therapy. This cell-free biologic is essentially a collection of proteins and other factors produced by amnion-derived epithelial cells and is being studied for necrotizing enterocolitis. Brown explains the story behind this novel therapy, the GMP manufacturing process Noveome developed to produce it, and the CMC challenges it faces from a regulatory perspective. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

  ListenShow Notes
• 

  Better Biopharma

  The Editors’ Roundtable: A Midyear Look At The 2026 Life Sciences Industry

  Jun 2, 20261h 24mS0

  <p>In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by chief editors from across the Life Science Connect ecosystem to discuss what’s shaping the pharmaceutical industry in 2026. The editors reflect on recent developments in their respective spaces and make predictions on what the rest of the year has in store. They also highlight some exciting projects happening across their publications. </p><p>This roundtable features Katie Anderson, chief editor at Pharmaceutical Online; Jeff Buguliskis, Ph.D., deputy chief editor at Outsourced Pharma; Ben Comer, chief editor at Life Science Leader and host of The Business Of Biot...

  ListenShow Notes

Recent guests on Better Biopharma. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.